TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07617493: An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 551 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07617493 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07617493 Rescue Dossier →